0.14
+0.001(+0.71%)
Currency In USD
| Previous Close | 0.14 |
| Open | 0.14 |
| Day High | 0.14 |
| Day Low | 0.14 |
| 52-Week High | 1.95 |
| 52-Week Low | 0.11 |
| Volume | 14,579 |
| Average Volume | 44,359 |
| Market Cap | 1.13M |
| PE | -0.07 |
| EPS | -1.94 |
| Moving Average 50 Days | 0.15 |
| Moving Average 200 Days | 0.54 |
| Change | 0 |
If you invested $1000 in ZyVersa Therapeutics, Inc. (ZVSA) since IPO date, it would be worth $0.04 as of November 10, 2025 at a share price of $0.141. Whereas If you bought $1000 worth of ZyVersa Therapeutics, Inc. (ZVSA) shares 2 years ago, it would be worth $6.08 as of November 10, 2025 at a share price of $0.141.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
GlobeNewswire Inc.
Sep 10, 2025 11:55 AM GMT
Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.Cardiovascular complications are a leading cause of
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
GlobeNewswire Inc.
Sep 03, 2025 11:55 AM GMT
ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from kidney cells, and it upregulates cholesterol trans
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
GlobeNewswire Inc.
Aug 14, 2025 11:55 AM GMT
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstr